Brett Stephenson, PharmD

Director, Health Economics Outcomes Research
Arcutis Biotherapeutics, Inc.

Poster(s):

• (101) Improvement in atopic dermatitis signs and symptoms with once-daily and proactive twice-weekly roflumilast cream 0.15% or 0.05%: results from the 52-week phase 3 INTEGUMENT-OLE trial in patients aged ≥2 years
  Wednesday, October 29, 2025

• (102) Caregiver-reported outcomes from the phase 3 INTEGUMENT-PED trial of children aged 2–5 years with atopic dermatitis and treated with roflumilast cream 0.05%
  Wednesday, October 29, 2025

• (103) Efficacy and safety of roflumilast foam 0.3% in patients with psoriasis of the scalp and body in the phase 3 ARRECTOR trial
  Wednesday, October 29, 2025

• (104) Prevalence and advanced systemic treatment prescription patterns for scalp psoriasis in the real-world dermatology setting in the United States
  Wednesday, October 29, 2025